December - 2022

Companies in the News

DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions

The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...

Federation Bio Administers First Dose in Phase 1 Clinical Trial

- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...